CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
Public ClinicalTrials.gov record NCT05333874. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective: 1\) To examine the impact of Circulating tumor DNA (ctDNA) (expressed as mean tumor molecules per ml) on treatment decision making in patients with early stage breast cancer after neoadjuvant therapy and surgery Secondary Objectives: 1. Understand ctNDA kinetics in the neoadjuvant and adjuvant setting 2. To identify any associations between clinical staging and measurable ctDNA
Study identification
- NCT ID
- NCT05333874
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 34 participants
Conditions and interventions
Conditions
Interventions
- Neoadjuvant chemotherapy administered before surgical extraction of a tumor Drug
- Observational Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 5, 2022
- Primary completion
- Nov 27, 2027
- Completion
- Nov 27, 2027
- Last update posted
- Feb 8, 2026
2022 – 2027
United States locations
- U.S. sites
- 12
- U.S. states
- 1
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Trinitas Hospital and Comprehensive Cancer Center | Elizabeth | New Jersey | 07202 | — |
| RWJBarnabas Health - Robert Wood Johnson University Hospital | Hamilton | New Jersey | 08690 | — |
| Jersey City Medical Center | Jersey City | New Jersey | 07302 | — |
| Monmouth Medical Center - Southern Campus | Lakewood | New Jersey | 08701 | — |
| Cooperman Barnabas Medical Center | Livingston | New Jersey | 07052 | — |
| Monmouth Medical Center | Long Branch | New Jersey | 07740 | — |
| Robert Wood Johnson University Hospital | New Brunswick | New Jersey | 08901 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Newark Beth Israel Medical Center | Newark | New Jersey | 07112 | — |
| Robert Wood Johnson Barnabas Hospital -Somerset | Somerville | New Jersey | 08876 | — |
| Steeplechase Cancer Center | Somerville | New Jersey | 08876 | — |
| Monmouth Medical Center Vantage Point Infusion Cente | West Long Branch | New Jersey | 07746 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05333874, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 8, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05333874 live on ClinicalTrials.gov.